Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 02 12 2021
accepted: 21 03 2022
pubmed: 21 4 2022
medline: 7 7 2022
entrez: 20 4 2022
Statut: ppublish

Résumé

Upward economic mobility represents the ability of children to surpass their parents financially and improve their economic status. The extent to which it contributes to socioeconomic disparities in health outcomes remains largely unknown. Patients diagnosed with hepatocellular carcinoma (HCC) in 2004-2015 were identified from the SEER-Medicare linked database. Information on county-level upward economic mobility was obtained from the Opportunity Atlas, and its impact on early-stage diagnosis (tumor size ≤ 5 cm, no nodal involvement or distant metastases, no major vascular invasion or extrahepatic extension) and receipt of curative-intent treatment (resection, transplantation, or ablation) was examined. Among 9190 Medicare beneficiaries diagnosed with HCC, the majority were White (64.9%, n = 5965). Overall, 44.7% (n = 4105) of patients were diagnosed with early-stage HCC and 29.7% (n = 2731) underwent curative-intent treatment. While higher upward economic mobility was not associated with HCC diagnosis at an early stage (OR 0.94, 95% CI 0.83-1.06), patients with early-stage HCC from areas of high upward economic mobility had increased odds of undergoing curative-intent treatment (OR 1.25, 95% CI 1.03-1.51). Upward economic mobility had no impact on the likelihood to undergo curative-intent treatment for early-stage HCC among White (OR 1.15, 95% CI 0.91-1.45), Black (OR 1.94, 95% CI 0.85-4.45) or Asian patients (OR 0.77, 95% CI 0.44-1.36). In contrast, non-White patients other than Blacks or Asians diagnosed with early-stage HCC had markedly higher odds of receiving curative-intent treatment if the individual resided in an area characterized by higher versus lower upward economic mobility (OR 2.58, 95% CI 1.50-4.46). While community-level economic mobility was not associated with stage of diagnosis, it affected the likelihood of undergoing curative-intent treatment for early-stage HCC, especially among minority patients other than Black or Asian patients.

Sections du résumé

BACKGROUND BACKGROUND
Upward economic mobility represents the ability of children to surpass their parents financially and improve their economic status. The extent to which it contributes to socioeconomic disparities in health outcomes remains largely unknown.
METHODS METHODS
Patients diagnosed with hepatocellular carcinoma (HCC) in 2004-2015 were identified from the SEER-Medicare linked database. Information on county-level upward economic mobility was obtained from the Opportunity Atlas, and its impact on early-stage diagnosis (tumor size ≤ 5 cm, no nodal involvement or distant metastases, no major vascular invasion or extrahepatic extension) and receipt of curative-intent treatment (resection, transplantation, or ablation) was examined.
RESULTS RESULTS
Among 9190 Medicare beneficiaries diagnosed with HCC, the majority were White (64.9%, n = 5965). Overall, 44.7% (n = 4105) of patients were diagnosed with early-stage HCC and 29.7% (n = 2731) underwent curative-intent treatment. While higher upward economic mobility was not associated with HCC diagnosis at an early stage (OR 0.94, 95% CI 0.83-1.06), patients with early-stage HCC from areas of high upward economic mobility had increased odds of undergoing curative-intent treatment (OR 1.25, 95% CI 1.03-1.51). Upward economic mobility had no impact on the likelihood to undergo curative-intent treatment for early-stage HCC among White (OR 1.15, 95% CI 0.91-1.45), Black (OR 1.94, 95% CI 0.85-4.45) or Asian patients (OR 0.77, 95% CI 0.44-1.36). In contrast, non-White patients other than Blacks or Asians diagnosed with early-stage HCC had markedly higher odds of receiving curative-intent treatment if the individual resided in an area characterized by higher versus lower upward economic mobility (OR 2.58, 95% CI 1.50-4.46).
CONCLUSIONS CONCLUSIONS
While community-level economic mobility was not associated with stage of diagnosis, it affected the likelihood of undergoing curative-intent treatment for early-stage HCC, especially among minority patients other than Black or Asian patients.

Identifiants

pubmed: 35441305
doi: 10.1245/s10434-022-11726-7
pii: 10.1245/s10434-022-11726-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5177-5185

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. Society of Surgical Oncology.

Références

International Agency for Research on Cancer. Cancer Today. Data visualization tools for exploring the global cancer burden in 2020. Accessed November 3, 2021, https://gco.iarc.fr/today/home
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer ctatistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654 .
doi: 10.3322/caac.21654 pubmed: 33433946
Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx030 .
doi: 10.1093/jnci/djx030 pubmed: 29117389 pmcid: 6279288
American Cancer Society. Liver cancer survival rates. Updated January 29, 2021. Accessed November 3, 2021, https://www.cancer.org/cancer/liver-cancer/detection-diagnosis-staging/survival-rates.html#references
Howlander N, Noone AM, Krapcho M, Miller D. SEER Cancer Statistics Review, 1975-2017. 2020. Accessed April 2021. https://seer.cancer.gov/csr/1975_2017/
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 5.2021. Updated September 21, 2021. Accessed November 3, 2021, https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116(5):1367–77. https://doi.org/10.1002/cncr.24817 .
doi: 10.1002/cncr.24817 pubmed: 20101732
Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and ethnic disparities in survival among patients with hepatocellular carcinoma in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.12.029 .
doi: 10.1016/j.cgh.2020.12.029 pubmed: 33387668
Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer. 2020;127(1):45–55. https://doi.org/10.1002/cncr.33211 .
doi: 10.1002/cncr.33211 pubmed: 33103243
Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health. 2010;100(Suppl 1):S186–96. https://doi.org/10.2105/AJPH.2009.166082 .
doi: 10.2105/AJPH.2009.166082 pubmed: 20147693 pmcid: 2837459
Anyiwe K, Qiao Y, De P, Yoshida EM, Earle CC, Thein HH. Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a population-based cohort study. Liver Int. 2016;36(6):902–10. https://doi.org/10.1111/liv.12982 .
doi: 10.1111/liv.12982 pubmed: 26455359
Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol. 2016;50(5):423–30. https://doi.org/10.1097/MCG.0000000000000448 .
doi: 10.1097/MCG.0000000000000448 pubmed: 26583267
Hoehn RS, Hanseman DJ, Jernigan PL, et al. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford). 2015;17(9):747–52. https://doi.org/10.1111/hpb.12427 .
doi: 10.1111/hpb.12427 pubmed: 26278321 pmcid: 4557647
Hoehn RS, Hanseman DJ, Wima K, et al. Does race affect management and survival in hepatocellular carcinoma in the United States? Surgery. 2015;158(5):1244–51. https://doi.org/10.1016/j.surg.2015.03.026 .
doi: 10.1016/j.surg.2015.03.026 pubmed: 25958069
Chetty R, Hendren N, Kline P, Saez E. Where is the land of opportunity? The geography of intergenerational mobility in the United States. Q J Econ. 2014;129(4):1553–623. https://doi.org/10.1093/qje/qju022 .
doi: 10.1093/qje/qju022
Mazumder B. Intergenerational mobility in the United States: what we have learned from the PSID. Ann Am Acad Pol Soc Sci. 2018;680(1):213–34. https://doi.org/10.1177/0002716218794129 .
doi: 10.1177/0002716218794129 pubmed: 31666747 pmcid: 6820674
Bratberg E, Mazumder J, Nybom B, Schnitzlein M, Vaage K. A comparison of intergenerational mobility curves in Germany Norway Sweden, and the US. Scand J Econ. 2016. https://doi.org/10.1111/sjoe.12197 .
doi: 10.1111/sjoe.12197
Davis JM. The decline in intergenerational mobility after 1980. Stone Center Working Paper Series. 2020;11
Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15(2):415–23. https://doi.org/10.1245/s10434-007-9658-3 .
doi: 10.1245/s10434-007-9658-3 pubmed: 17987343
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002. https://doi.org/10.1097/01.MLR.0000020942.47004.03 .
doi: 10.1097/01.MLR.0000020942.47004.03 pubmed: 12187174
Opportunity Insights. Data library. Accessed August 6, 2021, https://opportunityinsights.org/data/
Chetty R, Friedman JN, Hendren N, Jones MR, Porter SR. The opportunity atlas: mapping the childhood roots of social mobility. National Bureau of Economic Research Working Paper Series. 2018; doi: https://doi.org/10.3386/w25147
Nathan H, Hyder O, Mayo SC, et al. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258(6):1022–7. https://doi.org/10.1097/SLA.0b013e31827da749 .
doi: 10.1097/SLA.0b013e31827da749 pubmed: 23299519
Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249(5):799–805. https://doi.org/10.1097/SLA.0b013e3181a38eb5 .
doi: 10.1097/SLA.0b013e3181a38eb5 pubmed: 19387322
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9. https://doi.org/10.1097/01.mlr.0000182534.19832.83 .
doi: 10.1097/01.mlr.0000182534.19832.83 pubmed: 16224307
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82. https://doi.org/10.1093/aje/kwq433 .
doi: 10.1093/aje/kwq433 pubmed: 21330339
Azap RA, Hyer JM, Diaz A, Paredes AZ, Pawlik TM. Association of county-level vulnerability, patient-level race/ethnicity, and receipt of surgery for early-stage hepatocellular carcinoma. JAMA Surg. 2021;156(2):197–9. https://doi.org/10.1001/jamasurg.2020.5554 .
doi: 10.1001/jamasurg.2020.5554 pubmed: 33355639
Adler NE, Glymour MM, Fielding J. Addressing social determinants of health and health inequalities. JAMA. 2016;316(16):1641–2. https://doi.org/10.1001/jama.2016.14058 .
doi: 10.1001/jama.2016.14058 pubmed: 27669456
World Health Organization. Social determinants of health. Accessed November 5, 2021, https://www.who.int/health-topics/social-determinants-of-health#tab=tab_1
Azap RA, Diaz A, Hyer JM, et al. Impact of race/ethnicity and county-level vulnerability on receipt of surgery among older Medicare beneficiaries with the diagnosis of early pancreatic cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09911-1 .
doi: 10.1245/s10434-021-09911-1 pubmed: 33844130
Hyer JM, Tsilimigras DI, Diaz A, et al. High social vulnerability and “textbook outcomes” after cancer operation. J Am Coll Surg. 2021;232(4):351–9. https://doi.org/10.1016/j.jamcollsurg.2020.11.024 .
doi: 10.1016/j.jamcollsurg.2020.11.024 pubmed: 33508426
Daly MC, Duncan GJ, McDonough P, Williams DR. Optimal indicators of socioeconomic status for health research. Am J Public Health. 2002;92(7):1151–7. https://doi.org/10.2105/ajph.92.7.1151 .
doi: 10.2105/ajph.92.7.1151 pubmed: 12084700 pmcid: 1447206
Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong RJ. Medicaid and uninsured hepatocellular carcinoma patients have more advanced tumor stage and are less likely to receive treatment. J Clin Gastroenterol. 2018;52(5):437–43. https://doi.org/10.1097/MCG.0000000000000859 .
doi: 10.1097/MCG.0000000000000859 pubmed: 28723861
Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med. 2015;163(3):226–8. https://doi.org/10.7326/M15-0320 .
doi: 10.7326/M15-0320 pubmed: 26121095
Wong RJ, Jain MK, Therapondos G, et al. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol. 2018;113(9):1329–38. https://doi.org/10.1038/s41395-018-0033-8 .
doi: 10.1038/s41395-018-0033-8 pubmed: 29523864
Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875–84. https://doi.org/10.1002/hep.28770 .
doi: 10.1002/hep.28770 pubmed: 27531684
Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128(1):90 e1-97. https://doi.org/10.1016/j.amjmed.2014.07.027 .
doi: 10.1016/j.amjmed.2014.07.027
Chetty R, Stepner M, Abraham S, et al. The association between income and life expectancy in the United States, 2001–2014. JAMA. 2016;315(16):1750–66. https://doi.org/10.1001/jama.2016.4226 .
doi: 10.1001/jama.2016.4226 pubmed: 27063997 pmcid: 4866586
Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38(7):703–12. https://doi.org/10.1111/apt.12450 .
doi: 10.1111/apt.12450 pubmed: 23957569 pmcid: 3777750
Fields GS, Ok EA. The meaning and measurement of income mobility. J Econ Theory. 1996;71(2):349–77.
doi: 10.1006/jeth.1996.0125
Darin-Mattsson A, Fors S, Kåreholt I. Different indicators of socioeconomic status and their relative importance as determinants of health in old age. Int J Equity Health. 2017;16(173)
The Bell Policy Center. What is Economic Mobility? Accessed August 19, 2021, www.bellpolicy.org/what-is-economic-mobility
Nathan H, Segev DL, Bridges JF, et al. Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol. 2013;20(2):448–56. https://doi.org/10.1245/s10434-012-2619-5 .
doi: 10.1245/s10434-012-2619-5 pubmed: 22941170
Diaz A, Hyer JM, Barmash E, Azap R, Paredes AZ, Pawlik TM. County-level social vulnerability is associated with worse surgical outcomes especially among minority patients. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004691 .
doi: 10.1097/SLA.0000000000004691 pubmed: 33214485
Paro A, Dalmacy D, Madison Hyer J, Tsilimigras DI, Diaz A, Pawlik TM. Impact of residential racial integration on postoperative outcomes among medicare beneficiaries undergoing resection for cancer. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10034-w .
doi: 10.1245/s10434-021-10034-w pubmed: 34599435
Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg. 2011;146(7):778–84. https://doi.org/10.1001/archsurg.2011.37 .
doi: 10.1001/archsurg.2011.37 pubmed: 21422327
Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145(12):1158–63. https://doi.org/10.1001/archsurg.2010.272 .
doi: 10.1001/archsurg.2010.272 pubmed: 21173289
David R, Collins C. US socioeconomic and racial differences in health: patterns and explanations. Annu Rev Sociol. 1995;21:349–86.
doi: 10.1146/annurev.so.21.080195.002025
Williams DR, Lavizzo-Mourey R, Warren RC. The concept of race and health status in America. Public Health Rep. 1994;109(1):26–41.
pubmed: 8303011 pmcid: 1402239
Hardy B, Logan T. Race and the lack of intergenerational economic mobility in the United States. Accessed August 19, 2021, https://equitablegrowth.org/race-and-the-lack-of-intergenerational-economic-mobility-in-the-united-states/
Hardy BL, Logan TD, Parman J. The historical role of race and policy for regional inequality. Place-Based Policies for Shared Economic Growth. 2018.
Chetty R, Hendren N, Jones MR, Porter SR. Race and economic opportunity in the United States: an intergenerational perspective. Q J Econ. 2020;135(2):711–83.
doi: 10.1093/qje/qjz042
Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg. Dec 2007;11(12):1636-46; discussion 1646. doi: https://doi.org/10.1007/s11605-007-0315-8
Pinheiro PS, Medina HN, Callahan KE, et al. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int. 2020;40(5):1201–10. https://doi.org/10.1111/liv.14409 .
doi: 10.1111/liv.14409 pubmed: 32087002 pmcid: 8637930
Maani N, Galea S. The role of physicians in addressing social determinants of health. JAMA. 2020;323(16):1551–2. https://doi.org/10.1001/jama.2020.1637 .
doi: 10.1001/jama.2020.1637 pubmed: 32242894

Auteurs

Alessandro Paro (A)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Djhenne Dalmacy (D)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Diamantis I Tslimigras (DI)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Jordan Cloyd (J)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Aslam Ejaz (A)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Timothy M Pawlik (TM)

Department of Surgery, James Cancer Hospital and Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. tim.pawlik@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH